Across TCGA pan-cancer cohorts, FBLN5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FBLN5 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher FBLN5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBLN5 expression acts as an unfavorable survival marker.
KICH, LUSC, and LIHC are the cancer types where FBLN5 Mutation most reproducibly stratifies survival.